XSpray Pharma AB (publ) logo

XSPRAY - XSpray Pharma AB (publ) Share Price

SEK135.5 -9.5  -6.6%

Last Trade - 12:13pm

Small Cap
Market Cap £213.5m
Enterprise Value £201.9m
Revenue £n/a
Position in Universe 611th / 1789
Unlock XSPRAY Revenue
Relative Strength (%)
1m -7.84%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 3.64 0.79 0.33 0.28 0.000 200 383 -100.0%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, XSpray PharmaAB (publ) revenues was not reported. Net loss increased 51%to SEK25.9M. Higher net loss reflects Selling/General/AdminExpense increase of 42% to SEK22.9M (expense), Research &Development Expense increase from SEK811K to SEK3.3M(expense), Other Operating Expense increase of 19% toSEK804K (expense). Basic Earnings per Share excludingExtraordinary Items decreased from -SEK1.13 to -SEK1.54.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for XSPRAY
Graphical History


XSPRAY Revenue Unlock XSPRAY Revenue

Net Income

XSPRAY Net Income Unlock XSPRAY Revenue

Normalised EPS

XSPRAY Normalised EPS Unlock XSPRAY Revenue

PE Ratio Range

XSPRAY PE Ratio Range Unlock XSPRAY Revenue

Dividend Yield Range

XSPRAY Dividend Yield Range Unlock XSPRAY Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
XSPRAY EPS Forecasts Unlock XSPRAY Revenue
Profile Summary

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since September 28, 2017
No. of Shareholders: n/a
No. of Employees: 20
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 16,751,622
Free Float (0.0%)
Eligible for
XSPRAY Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for XSPRAY
Upcoming Events for XSPRAY
Frequently Asked Questions for XSpray Pharma AB (publ)
What is the XSpray Pharma AB (publ) share price?

As of 12:13pm, shares in XSpray Pharma AB (publ) are trading at SEK135.5, giving the company a market capitalisation of £213.5m. This share price information is delayed by 15 minutes.

How has the XSpray Pharma AB (publ) share price performed this year?

Shares in XSpray Pharma AB (publ) are currently trading at SEK135.5 and the price has moved by 0.114k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the XSpray Pharma AB (publ) price has moved by 0.142k% over the past year.

What are the analyst and broker recommendations for XSpray Pharma AB (publ)?

Of the analysts with advisory recommendations for XSpray Pharma AB (publ), there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for XSpray Pharma AB (publ) is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will XSpray Pharma AB (publ) next release its financial results?

XSpray Pharma AB (publ) is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the XSpray Pharma AB (publ) dividend yield?

XSpray Pharma AB (publ) does not currently pay a dividend.

Does XSpray Pharma AB (publ) pay a dividend?

XSpray Pharma AB (publ) does not currently pay a dividend.

When does XSpray Pharma AB (publ) next pay dividends?

XSpray Pharma AB (publ) does not currently pay a dividend.

How do I buy XSpray Pharma AB (publ) shares?

To buy shares in XSpray Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of XSpray Pharma AB (publ)?

Shares in XSpray Pharma AB (publ) are currently trading at SEK135.5, giving the company a market capitalisation of £213.5m.

Where are XSpray Pharma AB (publ) shares listed? Where are XSpray Pharma AB (publ) shares listed?

Here are the trading details for XSpray Pharma AB (publ):

Country of listing: Sweden
Exchange: STO
Ticker Symbol: XSPRAY
What kind of share is XSpray Pharma AB (publ)?

Based on an overall assessment of its quality, value and momentum, XSpray Pharma AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a XSpray Pharma AB (publ) share price forecast 2020?

Shares in XSpray Pharma AB (publ) are currently priced at SEK135.5. At that level they are trading at 24.14% discount to the analyst consensus target price of 0.00.

Analysts covering XSpray Pharma AB (publ) currently have a consensus Earnings Per Share (EPS) forecast of 6.44 for the next financial year.

How can I tell whether the XSpray Pharma AB (publ) share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like XSpray Pharma AB (publ). Over the past six months, the relative strength of its shares against the market has been 0.121k%. At the current price of SEK135.5, shares in XSpray Pharma AB (publ) are trading at 31.48% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the XSpray Pharma AB (publ) PE Ratio?

We were not able to find PE ratio data for XSpray Pharma AB (publ).

Who are the key directors of XSpray Pharma AB (publ)?

We were unable to find the directors for XSpray Pharma AB (publ).

Who are the major shareholders of XSpray Pharma AB (publ)?

Here are the top five shareholders of XSpray Pharma AB (publ) based on the size of their shareholding:

√Ėstersj√∂stiftelsen Corporation
Percentage owned: 13.24% (2.50m shares)
Ribbskottet AB Corporation
Percentage owned: 9.9% (1.87m shares)
Swedbank Robur Fonder AB Investment Advisor/Hedge Fund
Percentage owned: 7.36% (1.39m shares)
Swedbank Robur Ny Teknik Mutual Fund
Percentage owned: 7.3% (1.38m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 7.24% (1.37m shares)
Similar to XSPRAY
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.